• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >A Systematic Review Assessing the Economic Impact of Sildenafil Citrate (Viagra?) in the Treatment of Erectile Dysfunction
【24h】

A Systematic Review Assessing the Economic Impact of Sildenafil Citrate (Viagra?) in the Treatment of Erectile Dysfunction

机译：评估枸of酸西地那非（Viagra？）对勃起功能障碍的经济影响的系统评价

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Sildenafil was the first oral phosphodiesterase type 5 (PDE5) inhibitor introduced as primary therapy for erectile dysfunction (ED). In the 7 years following its market launch, sildenafil was prescribed by more than 750,000 physicians to more than 23 million men worldwide. To date, few studies have evaluated the economic impact of sildenafil in treating ED. Aim.: To evaluate the cost-effectiveness and impact of sildenafil on health care costs for patients with ED in multiple countries. Main Outcomes Measures.: Economic outcomes including cost, cost-effectiveness, cost of illness, cost consequence, resource use, productivity, work loss, and willingness to pay (WTP) were investigated. Methods.: Using keywords related to economic outcomes and sildenafil, we systematically searched literature published between July 2001 and July 2011 using MEDLINE and EMBASE. Included articles pertained to costs, WTP, and economic evaluations. Results.: In the last 10 years, 12 studies assessed economic outcomes associated with sildenafil for ED. Most studies were conducted in the United States and the United Kingdom, with one study identified in Canada and one from Mexico. Six studies evaluated cost of illness, cost consequence, or cost of care, and four studies evaluated WTP or drug pricing by country in the United States and the United Kingdom. In the United States and the United Kingdom, costs to health care systems have increased with demand for treatment. Cost analyses suggested that sildenafil would lower direct costs compared with other PDE5 inhibitors. US and UK studies found that patients exhibited WTP for sildenafil. The two cost-effectiveness models we identified examined ED sub-groups, those with spinal cord injury and those with diabetes or hypertension. These models indicated favorable cost-effectiveness profiles for sildenafil compared with other active-treatment options in both Mexico and Canada. Conclusions.: The relative value of sildenafil vs. surgically implanted prosthetic devices and other PDE5 inhibitors, is underscored by patients' WTP, and cost-effectiveness in ED patients with comorbidities.
机译：简介：西地那非是第一种作为勃起功能障碍（ED）的主要疗法而引入的口服5型磷酸二酯酶（PDE5）抑制剂。在市场推出后的7年中，西地那非被超过75万名医生开处方给全球超过2300万名男性。迄今为止，很少有研究评估西地那非治疗ED的经济影响。目的：评估西地那非在多个国家对ED患者的成本效益和对医疗费用的影响。主要成果指标：研究了经济成果，包括成本，成本效益，疾病成本，成本后果，资源使用，生产力，工作损失和支付意愿（WTP）。方法：使用与经济成果和西地那非有关的关键字，我们使用MEDLINE和EMBASE系统搜索了2001年7月至2011年7月之间发表的文献。包括有关成本，污水处理厂和经济评估的文章。结果：在过去10年中，有12项研究评估了与昔多芬治疗ED相关的经济成果。大多数研究是在美国和英国进行的，其中一项是在加拿大，另一项是在墨西哥。六项研究评估了疾病成本，成本后果或护理成本，四项研究评估了美国和英国按国家/地区划分的WTP或药品定价。在美国和英国，医疗保健系统的成本随着治疗需求的增加而增加。成本分析表明，西地那非与其他PDE5抑制剂相比将降低直接成本。美国和英国的研究发现，患者对西地那非表现出WTP。我们确定了两个成本效益模型，以检查ED亚组，即脊髓损伤者和糖尿病或高血压者。与墨西哥和加拿大的其他积极治疗方案相比，这些模型表明西地那非具有良好的成本效益。结论：西地那非与手术植入的假体装置和其他PDE5抑制剂的相对价值被患者的WTP和在合并症的ED患者中的成本效益所强调。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号